OTC Markets OTCPK - Delayed Quote USD

WuXi Biologics (Cayman) Inc. (WXXWY)

11.24 -0.28 (-2.45%)

At close: October 30 at 4:00:00 PM EDT

WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026

PR Newswire 9d ago

2269.HK
Can WuXi Biologics (Cayman) (SEHK:2269) Stay Reasonable As Capacity Expands?

Simply Wall St. 10d ago

2269.HK
WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence

PR Newswire 16d ago

2269.HK

2269
Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption

GlobeNewswire 29d ago

2269.HK

BIO

SYNGENE.NS
WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability

PR Newswire 1mo ago

2269.HK

2269
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership

PR Newswire 1mo ago

2269.HK

2269
Big Pharma Is Pouring Billions Into China’s Biotechs

Barrons.com 1mo ago

AZN

ZLAB

1093.HK
WuXi Biologics Reports Strong Profitable Growth in H1 2026

PR Newswire 2mo ago

2269.HK

2268.HK
WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO

PR Newswire 2mo ago

2269.HK

MRK

LLY
Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story

Simply Wall St. 8mo ago

VRTX

WXIBF
Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis

Simply Wall St. 8mo ago

VRTX

WXIBF
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

PR Newswire 9mo ago

WXIBF

WXXWY
-2.45%

U.S. markets closed

WuXi Biologics (Cayman) Inc. (WXXWY)

WuXi Biologics Receives Top-Honor Jade Award at The Asset Corporate Sustainability Leadership Awards 2026

Can WuXi Biologics (Cayman) (SEHK:2269) Stay Reasonable As Capacity Expands?

WuXi Biologics Continues to Be Included in Multiple Hang Seng Sustainability Indexes, Demonstrating ESG Excellence

Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption

WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability

WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership

Big Pharma Is Pouring Billions Into China’s Biotechs

WuXi Biologics Reports Strong Profitable Growth in H1 2026

WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO

Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story

Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic